Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of stereotactic intracerebral transplantation of XS411 cell injection for Parkinson's disease
CTR20261463Phase 2Active
- Sponsor
- XellSmart Biomedical
- Start
- May 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of XS-411 in Parkinson's disease (PD), sponsored by XellSmart Biomedical. Started May 2026; status: active.
02
Drugs
XS-411
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20261463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261463.